These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 32786308)
1. Filtering out Low-Affinity Bitropic Ligands for Dopamine Receptors Based on Ligand Conformation. Hayatshahi HS; Liu J ACS Chem Neurosci; 2020 Sep; 11(17):2523-2527. PubMed ID: 32786308 [TBL] [Abstract][Full Text] [Related]
2. Factors Governing Selectivity of Dopamine Receptor Binding Compounds for D2R and D3R Subtypes. Hayatshahi HS; Luedtke RR; Taylor M; Chen PJ; Blass BE; Liu J J Chem Inf Model; 2021 Jun; 61(6):2829-2843. PubMed ID: 33988991 [TBL] [Abstract][Full Text] [Related]
3. Analogues of Arylamide Phenylpiperazine Ligands To Investigate the Factors Influencing D3 Dopamine Receptor Bitropic Binding and Receptor Subtype Selectivity. Hayatshahi HS; Xu K; Griffin SA; Taylor M; Mach RH; Liu J; Luedtke RR ACS Chem Neurosci; 2018 Dec; 9(12):2972-2983. PubMed ID: 30010318 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands. Cao Y; Min C; Acharya S; Kim KM; Cheon SH Bioorg Med Chem; 2016 Jan; 24(2):191-200. PubMed ID: 26707842 [TBL] [Abstract][Full Text] [Related]
5. Synthesis of bitopic ligands based on fallypride and evaluation of their affinity and selectivity towards dopamine D Tian GL; Hsieh CJ; Taylor M; Lee JY; Riad AA; Luedtke RR; Mach RH Eur J Med Chem; 2023 Dec; 261():115751. PubMed ID: 37688938 [TBL] [Abstract][Full Text] [Related]
6. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor. Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613 [TBL] [Abstract][Full Text] [Related]
7. Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D Moritz AE; Bonifazi A; Guerrero AM; Kumar V; Free RB; Lane JR; Verma RK; Shi L; Newman AH; Sibley DR ACS Chem Neurosci; 2020 Oct; 11(20):3309-3320. PubMed ID: 32969645 [TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. Newman AH; Beuming T; Banala AK; Donthamsetti P; Pongetti K; LaBounty A; Levy B; Cao J; Michino M; Luedtke RR; Javitch JA; Shi L J Med Chem; 2012 Aug; 55(15):6689-99. PubMed ID: 22632094 [TBL] [Abstract][Full Text] [Related]
9. Aromatic linker variations in novel dopamine D Di Biase C; Leitzbach L; Frank A; Zivkovic A; Stark H Arch Pharm (Weinheim); 2024 Aug; 357(8):e2400071. PubMed ID: 38736025 [TBL] [Abstract][Full Text] [Related]
10. Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D Shaik AB; Boateng CA; Battiti FO; Bonifazi A; Cao J; Chen L; Chitsazi R; Ravi S; Lee KH; Shi L; Newman AH J Med Chem; 2021 Oct; 64(20):15313-15333. PubMed ID: 34636551 [TBL] [Abstract][Full Text] [Related]
11. The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors. Verma RK; Abramyan AM; Michino M; Free RB; Sibley DR; Javitch JA; Lane JR; Shi L PLoS Comput Biol; 2018 Jan; 14(1):e1005948. PubMed ID: 29337986 [TBL] [Abstract][Full Text] [Related]
13. The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D Battiti FO; Cemaj SL; Guerrero AM; Shaik AB; Lam J; Rais R; Slusher BS; Deschamps JR; Imler GH; Newman AH; Bonifazi A J Med Chem; 2019 Jul; 62(13):6287-6314. PubMed ID: 31257877 [TBL] [Abstract][Full Text] [Related]
14. Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D Reilly SW; Riad AA; Hsieh CJ; Sahlholm K; Jacome DA; Griffin S; Taylor M; Weng CC; Xu K; Kirschner N; Luedtke RR; Parry C; Malhotra S; Karanicolas J; Mach RH J Med Chem; 2019 May; 62(10):5132-5147. PubMed ID: 31021617 [TBL] [Abstract][Full Text] [Related]
15. Chiral Cyclic Aliphatic Linkers as Building Blocks for Selective Dopamine D Battiti FO; Zaidi SA; Katritch V; Newman AH; Bonifazi A J Med Chem; 2021 Nov; 64(21):16088-16105. PubMed ID: 34699207 [TBL] [Abstract][Full Text] [Related]
16. Unraveling Activation-Related Rearrangements and Intrinsic Divergence from Ligand-Specific Conformational Changes of the Dopamine D3 and D2 Receptors. Lee KH; Shi L J Chem Inf Model; 2024 Mar; 64(6):1778-1793. PubMed ID: 38454785 [TBL] [Abstract][Full Text] [Related]
17. Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity. Zou MF; Keck TM; Kumar V; Donthamsetti P; Michino M; Burzynski C; Schweppe C; Bonifazi A; Free RB; Sibley DR; Janowsky A; Shi L; Javitch JA; Newman AH J Med Chem; 2016 Apr; 59(7):2973-88. PubMed ID: 27035329 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of arylpiperazine-reverse amides as biased dopamine D3 receptor ligands. Cao Y; Paudel S; Zhang X; Kim KM; Cheon SH Bioorg Med Chem; 2015 Sep; 23(17):5264-72. PubMed ID: 26278029 [TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol. Paul NM; Taylor M; Kumar R; Deschamps JR; Luedtke RR; Newman AH J Med Chem; 2008 Oct; 51(19):6095-109. PubMed ID: 18774793 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D Cao Y; Sun N; Zhang J; Liu Z; Tang YZ; Wu Z; Kim KM; Cheon SH Medchemcomm; 2018 Sep; 9(9):1457-1465. PubMed ID: 30288220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]